Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Sicking, Isabel ^a   Edlund, Karolina ^b   Wesbuer, Eva ^a   Weyer, Veronika ^a   Battista, Marco J ^a   Lebrecht, Antje ^a   Solbach, Christine ^a   Grinberg, Marianna ^b   Lotz, Johannes ^a   Hoffmann, Gerald ^a   Rahnenführer, Jörg ^b   Hengstler, Jan G ^b   Schmidt, Marcus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATION; LYMPH NODE NEGATIVE BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PROTEIN BLOOD LEVEL; TUMOR NECROSIS; TUMOR VOLUME; BLOOD; BREAST NEOPLASMS; CELL PROLIFERATION; COHORT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN GENOME; LYMPH NODE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CELL PROLIFERATION; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; INFLAMMATION; KI-67 ANTIGEN; LYMPH NODES; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84908574988     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111306     Document Type: Article

References (38)

1. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420 (6917): 860-867. Available: doi: 10.1038/nature01322.
2. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68 (13): 5405-5413. Available: doi: 10.1158/0008-5472.CAN-07-5206.
3. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, et al. (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin k C as a compatible prognostic marker in human solid tumors. Clin. Cancer Res. 18 (9): 2695-2703. Available: doi: 10.1158/1078-0432.CCR-11-2210.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (5795): 1960-1964. Available: doi: 10.1126/science.1129139.
5. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, et al. (2009) CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 10 (9): 877-884. Available: doi: 10.1016/S1470-2045(09)70186-X.
6. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J. Clin. Invest. 117 (5): 1137-1146. Available: doi: 10.1172/JCI31405.
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144 (5): 646-674. Available: doi: 10.1016/j.cell.2011.02.013.
8. Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27 (13): 2217-2224. Available: doi: 10.1200/JCO.2008.19.8440.
9. Crumley ABC, McMillan DC, McKernan M, Going JJ, Shearer CJ, et al. (2006) An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br. J. Cancer 94 (11): 1568-1571. Available: doi: 10.1038/sj.bjc.6603150.
10. Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdle CS, et al. (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br. J. Cancer 87 (3): 264-267. Available: doi: 10.1038/sj.bjc.6600466.
11. McArdle PA, Mir K, Almushatat ASK, Wallace AM, Underwood MA, et al. (2006) Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol. Int. 77 (2): 127-129. Available: doi: 10.1159/000093905.
12. Mortensen RF (2001) C-reactive protein, inflammation, and innate immunity. Immunol. Res. 24 (2): 163-176. Available: doi: 10.1385/IR:24:2:163.
13. Han Y, Mao F, Wu Y, Fu X, Zhu X, et al. (2011) Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int. J. Biol. Markers 26 (4): 209-215. Available: doi: 10.5301/JBM.2011.8872.
14. Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, et al. (2007) Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br. J. Cancer 96 (6): 891-895. Available: doi: 10.1038/sj.bjc.6603682.
15. Tibau A, Ennis M, Goodwin PJ (2013) Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. Breast Cancer Res. Treat. 141 (3): 485-493. Available: doi: 10.1007/s10549-013-2694-8.
16. Ravishankaran P, Karunanithi R (2011) Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 9: 18. Available: doi: 10.1186/1477-7819-9-18.
17. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE (2011) Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 13 (3): R55. Available: doi: 10.1186/bcr2891.
18. Albuquerque KV, Price MR, Badley RA, Jonrup I, Pearson D, et al. (1995) Pretreatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol 21 (5): 504-509.
19. Heys SD, Ogston KN, Simpson WG, Walker LG, Hutcheon AW, et al. (1998) Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. Int. J. Oncol. 13 (3): 589-594.
20. O'Hanlon DM, Lynch J, Cormican M, Given HF (2002) The acute phase response in breast carcinoma. Anticancer Res. 22 (2B): 1289-1293.
21. Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, et al. (2009) Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer - comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann. Oncol. 20 (2): 258-264. Available: doi: 10.1093/annonc/mdn590.
22. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (5): 403-410.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 100 (2): 229-235. Available: doi: 10.1007/s10549-006-9242-8.
24. Altman DG, Andersen PK (1989) Bootstrap investigation of the stability of a Cox regression model. Stat Med 8 (7): 771-783.
25. Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11 (16): 2093-2109.
26. Reis-Alves SC, Traina F, Harada G, Campos PM, Saad STO, et al. (2013) Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. PLoS ONE 8 (12): e81048. Available: doi: 10.1371/journal.pone.0081048.
27. Ferro DP, Falconi MA, Adam RL, Ortega MM, Lima CP, et al. (2011) Fractal characteristics of May-Grünwald-Giemsa stained chromatin are independent prognostic factors for survival in multiple myeloma. PLoS ONE 6 (6): e20706. Available: doi: 10.1371/journal.pone.0020706.
28. Metze K (2008) Dichotomization of continuous data - a pitfall in prognostic factor studies. Pathol. Res. Pract. 204 (3): 213-214. Available: doi: 10.1016/j.prp.2007.12.002.
29. Metze K (2011) Pitfalls in the assessment of prognostic factors. Lancet Oncol. 12 (12): 1095-1096. Available: doi: 10.1016/S1470-2045(11)70309-6.
30. Metze K (2011) Dichotomizing continuous prognostic factors can cause paradoxical results in survival models. J. Am. Coll. Surg. 212 (1): 132-134. Available: doi: 10.1016/j.jamcollsurg.2010.10.004.
31. Schmidt M, Koelbl H (2012) Adjuvant chemotherapy in early breast cancer. Minerva Ginecol 64 (1): 53-65.
32. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (25): 1999-2009. Available: doi: 10.1056/NEJMoa021967.
33. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (27): 2817-2826. Available: doi: 10.1056/NEJMoa041588.
34. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, et al. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17 (18): 6012-6020. Available: doi: 10.1158/1078-0432.CCR-11-0926.
35. Heikkilä K, Ebrahim S, Lawlor DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61 (9): 824-833. Available: doi: 10.1136/jech.2006.051292.
36. Yigit E, Gönüllü G, Yücel I, Turgut M, Erdem D, et al. (2008) Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur. J. Intern. Med. 19 (8): 602-607. Available: doi: 10.1016/j.ejim.2007.06.036.
37. Robertson JF, Pearson D, Price MR, Selby C, Pearson J, et al. (1991) Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol. Immunother. 33 (6): 403-410.
38. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, et al. (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27 (21): 3437-3444. Available: doi: 10.1200/JCO.2008.18.9068.